A new drug called S14G-humanin (HNG) reduced kidney damage by 49.5% in diabetic mice and cut harmful cell death markers by 52.2%, according to Gram Research analysis. The compound works by stopping a destructive process in kidney cells’ mitochondria that normally leads to kidney damage in diabetes. While these results are promising, the research is still in early animal and cell stages—human trials are needed before this treatment becomes available to patients.
Researchers have discovered that a new compound called S14G-humanin (HNG) may help protect kidneys damaged by diabetes. In studies with diabetic mice, HNG reduced kidney damage by nearly half and prevented harmful cell death in kidney tubes. According to Gram Research analysis, the drug works by stopping a destructive process inside cells’ power plants (mitochondria) that normally leads to kidney damage. While these results are promising, the research is still in early stages using animal models and lab cells, so more testing in humans is needed before this treatment becomes available.
Key Statistics
A 2026 research study found that high-dose S14G-humanin reduced urinary albumin-to-creatinine ratio (a key marker of kidney damage) by 49.5% in diabetic mice compared to untreated diabetic mice.
According to research reviewed by Gram, S14G-humanin reduced p-MLKL expression (a marker of harmful cell death) by 52.2% in diabetic mouse kidneys, suggesting it blocks a destructive cellular process called necroptosis.
A 2026 study in the European Journal of Pharmacology found that the harmful necroptosis pathway was significantly more active in kidney tissue from diabetic patients compared to healthy controls, validating the relevance of this mechanism to human disease.
The Quick Take
- What they studied: Whether a new drug called S14G-humanin could protect kidneys from damage caused by diabetes
- Who participated: Diabetic mice created through diet and chemical injection, diabetic mice with genetic diabetes (db/db mice), and human kidney cells grown in a lab and exposed to high glucose and fat
- Key finding: High-dose HNG reduced the amount of protein leaking into urine (a sign of kidney damage) by 49.5% in diabetic mice and cut harmful cell death markers by 52.2%
- What it means for you: This research suggests a potential new treatment for diabetic kidney disease, but it’s still in early testing stages. People with diabetes should continue following their doctor’s current treatment plans while researchers work toward human trials
The Research Details
Scientists created diabetic mice by feeding them a high-fat diet and injecting them with a chemical that damages the pancreas. They then treated some mice with different doses of HNG and compared kidney damage between treated and untreated groups. The researchers also tested HNG in genetically diabetic mice and in human kidney cells grown in dishes and exposed to high glucose and fat to mimic diabetes conditions. They used multiple methods to examine the kidneys, including looking at tissue under a microscope, measuring specific proteins, and analyzing thousands of genes to understand how HNG works.
Testing in multiple models (different types of diabetic mice and human cells) strengthens confidence that the results aren’t just a fluke. By examining the detailed mechanism—how HNG stops harmful cell death—researchers can better understand whether this approach might work in humans and how to develop it further.
The study used well-established animal models of diabetes and included dose-response testing (testing different amounts of the drug). Results were confirmed across multiple systems. However, this is animal and cell research, not human studies, so results may not directly translate to people. The study was published in a peer-reviewed journal, indicating expert review of the methods
What the Results Show
HNG treatment significantly reduced kidney damage in diabetic mice in a dose-dependent manner, meaning higher doses worked better. The most impressive result was a 49.5% reduction in urinary albumin-to-creatinine ratio (UACR)—a key marker of kidney damage—dropping from 103.91 to 52.50 μg/mg. This improvement was statistically significant (P < 0.001), meaning it’s very unlikely to have happened by chance.
The researchers discovered HNG’s protective mechanism: it stops a harmful process called necroptosis (a type of cell death) in kidney tubules. Specifically, HNG reduced p-MLKL expression by 52.2%, a key marker of this destructive cell death pathway. The drug accomplished this by preventing mitochondria (the cell’s power plants) from leaking dangerous molecules and producing harmful free radicals that trigger cell death.
These findings held up when tested in genetically diabetic mice (db/db mice) and in human kidney cells exposed to high glucose and fat. Additionally, the researchers found that in actual kidney tissue from diabetic patients, the harmful necroptosis pathway was significantly more active than in healthy people, suggesting this mechanism is relevant to human disease.
HNG blocked mitochondrial BAX translocation (a step in the cell death process), reduced mitochondrial reactive oxygen species (ROS, or harmful free radicals), and prevented mitochondrial Z-DNA leakage. These effects collectively prevented ZBP1 activation, which is the master switch that triggers necroptosis. The compound showed protective effects across all tested systems, suggesting consistent biological activity.
This research builds on previous findings showing that humanin (the parent compound) has protective effects in various diseases. This is the first study specifically examining S14G-humanin in diabetic kidney disease. The focus on the Z-DNA/ZBP1 necroptosis pathway represents a newer understanding of how kidney damage occurs in diabetes, moving beyond traditional inflammation-focused approaches.
This study was conducted entirely in animals and cells, not humans. Results in mice don’t always translate to people due to differences in metabolism and physiology. The sample size of mice wasn’t specified in the abstract. The study doesn’t address long-term safety or whether HNG might interact with other medications. It’s unclear how HNG would be delivered to patients or what the optimal dosing would be in humans. More research is needed to determine if HNG is safe and effective in people with diabetes
The Bottom Line
This research is promising but preliminary. People with diabetic kidney disease should continue following their doctor’s current treatment recommendations (blood sugar control, blood pressure management, ACE inhibitors or ARBs). Discuss this research with your healthcare provider, but don’t expect HNG to be available as a treatment in the near future. Confidence level: Low to moderate (early-stage research)
This research is most relevant to people with type 1 or type 2 diabetes who have or are at risk for kidney disease. Healthcare providers and researchers studying diabetes complications should also pay attention. This is less immediately relevant to people without diabetes, though the underlying cell death mechanism might apply to other kidney diseases
This research is in the preclinical stage (animal and cell studies). If development proceeds, it typically takes 5-10+ years before a new drug reaches patients, including laboratory testing, animal safety studies, and multiple phases of human clinical trials
Frequently Asked Questions
What is S14G-humanin and how does it help diabetic kidneys?
S14G-humanin is a new drug that protects kidney cells from a type of harmful cell death called necroptosis. In diabetic mice, it reduced kidney damage markers by nearly 50% by stopping mitochondria (cell power plants) from leaking dangerous molecules that trigger cell death.
When will S14G-humanin be available as a treatment for diabetic kidney disease?
This research is still in early stages using animals and lab cells. Human clinical trials haven’t started yet. If development proceeds smoothly, it typically takes 5-10+ years before a new drug becomes available to patients.
Should I stop my current kidney disease medications and wait for this new drug?
No. Continue taking your current medications as prescribed by your doctor. This research is preliminary and not yet tested in humans. Current treatments like ACE inhibitors and blood sugar control remain the best-proven ways to protect your kidneys.
How does this research apply to people with type 1 versus type 2 diabetes?
The study used mice models of both type 1 and type 2 diabetes, so the findings may apply to both types. However, human studies are needed to confirm whether HNG works equally well in both groups and whether it’s safe for long-term use.
What should I do now if I have diabetic kidney disease?
Focus on proven strategies: keep blood sugar and blood pressure well-controlled, take prescribed kidney-protective medications (ACE inhibitors or ARBs), maintain a healthy diet low in salt and processed foods, and get regular kidney function tests to monitor your condition.
Want to Apply This Research?
- Track urinary albumin-to-creatinine ratio (UACR) through regular lab work ordered by your doctor. This is the same marker HNG reduced in the study. Monitor this quarterly or as recommended by your healthcare provider
- Use the app to log daily blood sugar readings and blood pressure measurements, as controlling these is currently the best way to slow diabetic kidney disease. Set reminders for taking prescribed medications like ACE inhibitors or ARBs that protect kidneys
- Create a long-term tracking dashboard showing kidney function tests (creatinine, eGFR) and UACR results from doctor visits. Compare trends over time to assess whether current treatments are working. Share this data with your healthcare provider at appointments
This article summarizes early-stage research conducted in animals and laboratory cells. S14G-humanin has not been tested in humans and is not approved by the FDA or any regulatory agency. The findings do not constitute medical advice. People with diabetic kidney disease should continue following their doctor’s current treatment recommendations and discuss any new research with their healthcare provider before making changes to their treatment plan. This research is promising but preliminary, and results in animals do not always translate to humans.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.